CureVac confirmed by email that Musk will visit the company in Tübingen this week, but said that there is no press release or press conference planned for the time being.
Musk tweeted on Sunday 30 August that: “Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.”
Electrek reported in July that a patent application revealed Tesla has been working with CureVac on a “bioreactor for RNA” for over a year. Tesla’s Grohmann engineering company in Prüm, in the Eifel region of Germany, is reportedly involved in developing the micro-factories for CureVac.
CureVac, which listed on the Nasdaq in August, is one of the leading German biotechs in the process of developing a potential m-RNA vaccine against COVID-19.
The German government invested €300m (£267m, $359m) in the privately-owned firm in June, taking a 23% stake, and British pharma giant GlaxoSmithKline (GSK) invested £130m for a 10% stake in July.
Musk said he was also planning to visit his new electric-car plant in Grünheide, Brandenburg this week. Construction of Tesla’s new Gigafactory the state surrounding Berlin, has been powering ahead since February this year.
The carmaker is still awaiting the final building permit and environmental approval, but plans to roll the first Model Y vehicles off the line by summer next year, targeting an eventual production volume of half a million units per year at full capacity, and employing around 10,000 staff. It also plans to eventually produce battery cells at the German site.
The factory site has attracted protests, mainly from locals, who are worried about the plant’s water usage, and environmental damage to the surrounding rural area.